Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U031 - Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy

Saturday, February 17; 7:30 AM - 8:30 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Diagnose and treat cutaneous toxicities to targeted and immune cancer therapies.
  • Recognize potential correlations between cutaneous toxicities and tumor response.
  • Use a team-based approach to manage cutaneous toxicities.

Description

This session will focus on updates in cutaneous toxicities to targeted and immune cancer therapy including BRAF inhibitors, EGFR inhibitors, and immune checkpoint inhibitors. This is a rapidly evolving field in both breadth of disease as well as management options, and this session is geared to the practicing clinician. Also, the significance of cutaneous toxicities will be reviewed including associations with increased tumor response. This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Patel, Anisha, MD: Spectrum – C(NC);
Schedule
Saturday, February 17
7:30 AM
Dr. Patel / Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy
Event Details
  • Date
    Saturday, February 17
  • Time
    7:30 AM - 8:30 AM
  • Location
    Room 8
  • CME Credits
    1.00
  • Type
    MOC
Directors/Co-Directors